Artemisia Annua Pollen

Dosage for Artemisia Annua Pollen extract is highly individualized and must be determined by a specialist based on the patient's sensitivity level, which is usually assessed via skin testing or serum IgE levels. There is no 'standard' dose for all patients.

Build-up Phase (Escalation)

During the initial phase, injections are typically given 1 to 3 times per week. The starting dose is usually very low (e.g., 0.05 mL of a highly diluted solution like 1:100,000 w/v). The dose is gradually increased at each visit—provided the patient tolerates the previous dose without a significant local or systemic reaction—until the 'maintenance dose' is reached. This phase usually lasts 3 to 6 months.

Maintenance Phase

Once the maintenance dose (the highest dose tolerated without significant side effects) is reached, the frequency of injections is decreased. Typically, the maintenance dose is administered once every 2 to 4 weeks. A common maintenance volume is 0.5 mL of the most concentrated vial (e.g., 1:20 w/v or 10,000 PNU/mL), but this varies significantly between manufacturers and patients.

Artemisia Annua Pollen extract is generally considered safe for use in children, typically starting around age 5. Dosing protocols for children are similar to those for adults, though the physician may exercise more caution during the build-up phase. The child must be able to communicate symptoms of a systemic reaction. It is not generally recommended for children under age 5 due to the difficulty in monitoring for early signs of anaphylaxis.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the proteins are not cleared by the kidneys in a manner that would lead to systemic toxicity. However, the patient's overall health must be stable.

Hepatic Impairment

No specific adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via general proteolytic pathways rather than the cytochrome P450 system.

Elderly Patients

Elderly patients may require more conservative dosing if they have underlying cardiovascular disease. The risk of using epinephrine (the treatment for a severe reaction) in patients with heart disease must be weighed against the benefits of immunotherapy.

Artemisia Annua Pollen extract is administered via subcutaneous injection, usually in the posterior aspect of the upper arm.

• Administration Site: The injection should be given deep subcutaneously. Intravascular injection must be avoided, as this significantly increases the risk of a systemic reaction.
• Observation Period: Patients MUST remain in the medical office for at least 30 minutes after every injection. Most fatal or near-fatal reactions occur within this window.
• Storage: Vials must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze. Potency can be lost if the extract is left at room temperature for extended periods.
• Food/Activity: There are no specific food restrictions, but patients should avoid vigorous exercise for at least 2 hours before and after the injection, as exercise increases blood flow and can accelerate allergen absorption, increasing the risk of a reaction.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a maintenance dose is missed by more than a week or two, the physician will typically reduce the dose for the next injection to ensure safety before gradually increasing back to the maintenance level.

An 'overdose' in the context of immunotherapy usually means the administration of too much allergen, leading to a systemic allergic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine is the primary treatment. The patient may also require oxygen, intravenous fluids, antihistamines, and corticosteroids. Emergency medical services (911) should be contacted immediately if a reaction occurs outside a clinical setting.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer these injections unless specifically trained and authorized by your physician in a home-use program (which is rare for SCIT).

Most patients receiving Artemisia Annua Pollen immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Injection Site Redness (Erythema): A red patch around the injection site is very common. It typically appears within minutes and may last for several hours.
• Local Swelling (Edema): A small 'wheal' or lump at the site of injection. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal local reaction.
• Itching (Pruritus): Localized itching at the injection site is a frequent occurrence.
• Nasal Congestion: Some patients may experience a mild 'flare' of their typical allergy symptoms shortly after the injection.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter. While not systemic, these often require a dosage adjustment for the next injection.
• Fatigue: A feeling of tiredness or 'heaviness' following the injection is reported by some patients.
• Headache: Mild to moderate headaches may occur within the first 24 hours of administration.
• Mild Urticaria: A few hives located away from the injection site.

• Generalized Body Aches: Flu-like symptoms that persist for a day after the injection.
• Persistent Cough: A dry, irritating cough that may indicate mild bronchial hyper-reactivity.
• Gastrointestinal Upset: Rare reports of mild nausea or abdominal cramping.

> Warning: Stop receiving Artemisia Annua Pollen injections and call your doctor or emergency services immediately if you experience any of the following symptoms of a systemic reaction:

• Anaphylaxis: A life-threatening, whole-body allergic reaction. Symptoms include a sudden drop in blood pressure, fainting, and severe difficulty breathing.
• Angioedema: Significant swelling of the lips, tongue, or throat that can obstruct the airway.
• Generalized Urticaria: Hives spreading rapidly across the entire body.
• Wheezing or Chest Tightness: Indicating an acute asthma exacerbation or bronchospasm.
• Cyanosis: A bluish tint to the skin or lips, indicating a lack of oxygen.
• Rapid or Weak Pulse: Signs of cardiovascular distress during a reaction.

There are no known 'toxic' long-term side effects of Artemisia Annua Pollen extract, as it is a biological protein that does not accumulate in organs. The primary long-term consideration is the potential for 'shifting' allergies—some patients may develop sensitivities to new allergens over time, though immunotherapy often helps prevent this 'allergic march.' Chronic local skin changes (like thickening or scarring) at the injection site are rare if sites are rotated properly.

While non-standardized extracts may not always carry a formal 'Black Box' on the outer carton in the same way as Sublingual Immunotherapy (SLIT) tablets, the FDA-approved prescribing information for all allergenic extracts contains a 'Warning' section equivalent to a black box regarding Anaphylaxis.

Summary of Warning: Artemisia Annua Pollen extract can cause severe, life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma are at a higher risk for fatal outcomes. Patients must be observed for at least 30 minutes post-injection. Certain medications, such as beta-blockers, may make a patient's reaction more difficult to treat.

Report any unusual symptoms to your healthcare provider. Your doctor may suggest taking an antihistamine before your injection to reduce the risk of minor local reactions, though this does not prevent anaphylaxis.

Artemisia Annua Pollen extract is a potent biological product. Safety is paramount, and the following precautions must be strictly observed. This medication is only intended for patients with a documented IgE-mediated allergy to Artemisia annua pollen. It is not a treatment for non-allergic rhinitis or other respiratory conditions.

No formal FDA black box warning exists for the specific non-standardized Artemisia Annua Pollen extract in the same format as newer drugs, but the class-wide warning for all allergenic extracts is critical. The primary risk is Anaphylaxis. Because of this risk, injections must be given in a clinical setting where emergency equipment (epinephrine, oxygen, IV fluids, and airway management) is immediately available. Patients should not receive an injection if they are currently experiencing a severe 'flare' of their allergy or asthma symptoms.

• Allergic Reactions / Anaphylaxis Risk: This is the most significant risk. Reactions can occur even in patients who have previously tolerated the same dose. The risk is higher during the build-up phase and during peak pollen season when the patient's 'allergic load' is already high.
• Asthma Stability: Patients with asthma must have their condition well-controlled (e.g., FEV1 > 80% of predicted) before receiving an injection. Uncontrolled asthma is the primary risk factor for fatal reactions to immunotherapy.
• Beta-Blocker Use: Patients taking beta-blockers (used for heart disease or high blood pressure) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This is a major precaution and often a contraindication.
• Acute Illness: If a patient has a fever or a respiratory infection, the injection should be postponed until they have recovered.

There are no routine lab tests (like blood counts or liver tests) required for Artemisia Annua Pollen therapy. However, clinical monitoring is intensive:

• Pre-Injection Assessment: The clinician will check the patient's current symptoms and may perform a peak flow meter test if the patient has asthma.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is required after every single dose.
• Site Inspection: The clinician will inspect the injection site for large local reactions before the patient leaves and before the next dose is administered.

Most patients can drive or operate machinery after the 30-minute observation period. However, if a patient feels dizzy, fatigued, or experiences any systemic symptoms, they should avoid these activities and notify medical staff immediately.

Alcohol should be avoided for several hours before and after an injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially increase the risk or severity of a systemic reaction.

If immunotherapy is discontinued for a period of time, it cannot be restarted at the previous dose. A 'step-down' in dosage is required to ensure safety. If a patient experiences a severe systemic reaction, the physician will carefully re-evaluate whether the benefits of continuing therapy outweigh the risks.

> Important: Discuss all your medical conditions with your healthcare provider before starting Artemisia Annua Pollen, especially any heart or lung issues.

• Beta-Adrenergic Antagonists (Beta-Blockers): This includes both systemic (e.g., Propranolol, Atenolol) and ophthalmic (e.g., Timolol eye drops) forms. These drugs can interfere with the action of epinephrine, which is the only life-saving treatment for anaphylaxis. A patient on a beta-blocker who has a reaction to an allergy shot may not respond to standard emergency treatment, leading to a fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some evidence suggests that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts, possibly due to the role of the renin-angiotensin system in modulating allergic responses.
• MAO Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): These medications can potentiate the effects of epinephrine, potentially leading to a hypertensive crisis if epinephrine must be administered for a reaction. However, they also make the management of anaphylaxis more complex.

• Other Immunotherapy: If a patient is receiving multiple types of immunotherapy (e.g., for dust mites or other pollens), the injections should ideally be given in different arms, and the doses must be carefully coordinated to avoid overwhelming the immune system.
• Antihistamines: While many patients take antihistamines to manage symptoms, these drugs can 'mask' the early warning signs of a systemic reaction (like mild itching or hives), potentially delaying the recognition of a serious problem.

• Alcohol: As mentioned, alcohol can increase blood flow and speed up the absorption of the allergen from the injection site. It is recommended to avoid alcohol on the day of the injection.
• High-Fat Meals: There is no direct interaction, but heavy meals may cause general discomfort that could be confused with a systemic reaction (e.g., nausea).

• St. John's Wort: May have minor interactions with the way the body handles stress and blood pressure, though not specifically documented with pollen extracts.
• Natural Vasodilators: Supplements that significantly affect blood pressure or heart rate should be discussed with the allergist.

• Skin Testing: Artemisia Annua Pollen immunotherapy will eventually decrease the patient's reactivity to skin prick tests for this pollen. This is an expected clinical outcome, not an 'interference' with the test.
• Serum IgE: Total and specific IgE levels may initially rise after starting therapy before eventually declining. This is a normal part of the immunological response.

For each major interaction, the mechanism usually involves either the pharmacodynamic blocking of emergency rescue medications (beta-blockers) or the physiological alteration of the body's response to an allergen (ACE inhibitors). The management strategy is usually to avoid the combination or to use extreme caution under the guidance of a specialist.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter eye drops and cold medicines.

Artemisia Annua Pollen extract must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients whose asthma is unstable or who have a low FEV1 (Forced Expiratory Volume) are at an extremely high risk of a fatal bronchial reaction if a systemic allergic response occurs. The lungs are already compromised, and the added stress of an allergic reaction can be catastrophic.
• Recent Myocardial Infarction or Unstable Angina: Because the treatment for a reaction (epinephrine) puts significant stress on the heart, patients with recent heart attacks or unstable chest pain should not receive immunotherapy.
• Known Hypersensitivity to Inactive Ingredients: If a patient is allergic to the preservatives (like phenol) or stabilizers (like glycerin) used in the extract, the product should not be used.
• Inability to Communicate: Patients who cannot express symptoms of a reaction (e.g., very young children or those with certain cognitive impairments) are not suitable candidates for SCIT.

These conditions require a careful risk-benefit analysis by the physician:

• Pregnancy: While not strictly contraindicated if the patient is already on a maintenance dose, starting new immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system could worsen certain autoimmune conditions, though evidence for this is limited.
• Malignancy: Patients with active cancer may have altered immune responses, making the efficacy and safety of immunotherapy unpredictable.

Patients allergic to Artemisia annua often show cross-reactivity with other members of the Artemisia genus (like A. vulgaris or Mugwort) and other plants in the Asteraceae family (like Ragweed, Chrysanthemums, or Marigolds). If a patient has had a severe reaction to one of these extracts, extreme caution must be used when introducing Artemisia Annua Pollen.

> Important: Your healthcare provider will evaluate your complete medical history and current health status before prescribing Artemisia Annua Pollen.

Artemisia Annua Pollen extract is typically classified in a manner similar to FDA Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.

• Risk Summary: The primary risk to the fetus is not the extract itself, but the potential for maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal death due to oxygen deprivation.
• Clinical Practice: Allergists generally do not start new immunotherapy build-up during pregnancy. However, if a patient is already at a stable maintenance dose and is tolerating it well, the therapy is often continued, as the risk of a reaction is lower during maintenance.

It is generally considered safe to continue Artemisia Annua Pollen immunotherapy while breastfeeding. The allergenic proteins are broken down in the mother's tissue and are not expected to pass into breast milk in any significant or harmful quantity. There is no evidence of adverse effects on the nursing infant.

• Approved Age: Immunotherapy is generally not started in children under the age of 5. This is primarily because younger children may not be able to articulate the early symptoms of a systemic reaction (such as an itchy throat or a sense of 'impending doom').
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.
• Benefits: Early intervention with immunotherapy in children with allergic rhinitis has been shown in some studies to reduce the risk of developing asthma later in life.

Patients over age 65 can receive Artemisia Annua Pollen immunotherapy, but the physician must carefully screen for cardiovascular disease.

• Risk Assessment: The elderly are more likely to be taking medications like beta-blockers or ACE inhibitors and are more susceptible to the cardiac stress of an allergic reaction or the epinephrine used to treat it.
• Clearance: Age-related changes in kidney or liver function do not significantly affect the processing of these protein extracts.

Patients with renal impairment do not require specific dose adjustments for Artemisia Annua Pollen extract. The proteins are metabolized by local and systemic proteases. However, these patients should be in stable health, and their fluid balance should be monitored if they require emergency treatment for a reaction.

No adjustments are needed for patients with liver disease. The liver's metabolic enzymes (CYP450) are not involved in the breakdown of the allergens contained in the extract.

> Important: Special populations require individualized medical assessment and often more frequent monitoring during the escalation phase of therapy.

Artemisia Annua Pollen extract acts as an immunomodulator. The primary molecular mechanism involves the induction of peripheral T-cell tolerance. During the build-up phase, the repeated exposure to the allergen proteins leads to the desensitization of mast cells and basophils. More importantly, it induces the production of T-regulatory (Treg) cells. These cells produce Interleukin-10 (IL-10), which signals B-cells to switch their antibody production from IgE (the allergy antibody) to IgG4 (a 'blocking' antibody). IgG4 can bind to the pollen allergens before they ever reach the IgE on the surface of mast cells, thereby preventing the release of histamine and other inflammatory mediators.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) generally lead to better long-term symptom relief. However, higher doses also increase the risk of systemic reactions.
• Onset of Effect: Clinical improvement is not immediate. It typically takes 3 to 6 months to notice a reduction in symptoms, with the full benefit often appearing after 12 to 18 months of consistent therapy.
• Duration of Effect: One of the unique aspects of immunotherapy is its 'disease-modifying' potential. After a successful 3-to-5-year course, many patients experience multi-year or even permanent remission of their allergy symptoms.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous injection) |

| Protein Binding | N/A (Processed by immune cells) |

| Half-life | Variable (Proteins degraded within hours/days) |

| Tmax | 30-60 minutes (Peak local concentration) |

| Metabolism | Local and systemic proteases |

| Excretion | Cellular metabolic pathways |

• Molecular Formula: Complex mixture of proteins (e.g., Art a 1, Art a 2).
• Molecular Weight: Varies by specific protein (typically 10 kDa to 70 kDa).
• Solubility: Soluble in aqueous buffered solutions (usually containing 0.9% NaCl and 0.4% phenol).
• Description: A clear to slightly hazy liquid, often yellowish or brownish depending on the concentration and source material.

Artemisia Annua Pollen belongs to the class of Non-Standardized Pollen Allergenic Extracts. Related medications include standardized extracts (like Short Ragweed or Grasses) and other non-standardized weed extracts (like Cocklebur or Pigweed).